Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | B2M over exp |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
B2M over exp | multiple myeloma | predicted - sensitive | Bortezomib | Preclinical | Actionable | In a preclinical study, B2M over expressing multiple myeloma cells resistant to Velcade (bortezomib) demonstrated increased apoptotic activity when treated with a combination of Velcade (bortezomib) and anti-beta 2 microglobulin monoclonal antibodies (PMID: 25895124). | 25895124 |